rs6067484 — PTPN1 PTPN1 rs6067484

Intronic PTPN1 tag SNP within the 100-kb T2D-risk haplotype block — carriers of the G allele have modestly higher PTP1B activity, reducing insulin and leptin signal duration and raising LDL cholesterol risk in lean individuals

See your personal result for PTPN1

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

PTP1B — The Off-Switch Your Insulin Receptor Fights Against

Every time you eat a carbohydrate, your pancreas releases insulin, which binds to receptors on muscle and fat cells and triggers a cascade that moves glucose from blood into cells. That signal is powerful — but it has to be turned off. The enzyme responsible for turning it off is PTP1B, encoded by the PTPN1 gene on chromosome 20. PTP1B is a protein tyrosine phosphatase11 protein tyrosine phosphatase
An enzyme that removes phosphate groups from tyrosine residues on activated receptors, terminating their signaling capacity that dephosphorylates the activated insulin receptor, shortening the window of insulin-driven glucose uptake. The same enzyme dephosphorylates JAK222 JAK2
Janus kinase 2, the first intracellular kinase activated when leptin binds its hypothalamic receptor in the hypothalamus, limiting leptin's appetite-suppressing and thermogenic signal as well. Too much PTP1B activity means every insulin pulse clears faster and every leptin signal resolves sooner — a metabolic brake applied to two of the body's most important metabolic hormones simultaneously.

rs6067484 sits within an intron of PTPN1, within the 100-kb haplotype block that harbors every PTPN1 variant associated with type 2 diabetes and insulin sensitivity. The G allele is a tag for the risk haplotype, and all the associated variants in this block are noncoding — pointing to altered gene regulation, rather than a changed protein, as the biological mechanism.

The Mechanism

The noncoding location of rs6067484 and its fellow-travelers in the PTPN1 LD block is mechanistically telling. One functional variant identified in the same region — a 3′-UTR insertion — was shown to increase PTPN1 mRNA stability in skeletal muscle33 increase PTPN1 mRNA stability in skeletal muscle
Bento et al. Diabetes, 2004 — the 3'-UTR insertion leads to higher PTPN1 transcript levels via increased mRNA stability, providing the molecular link between the risk haplotype and elevated PTP1B protein, resulting in more PTP1B protein being produced. The consequence is predictable: more PTP1B = faster dephosphorylation of the insulin receptor = shorter insulin signal duration = reduced glucose uptake per unit of insulin = insulin resistance.

The same pathway governs leptin sensitivity. PTP1B in the hypothalamus dephosphorylates JAK2, the kinase that initiates leptin signaling. When PTP1B is genetically elevated, leptin's inhibitory effect on appetite and its stimulation of energy expenditure are both blunted. This is precisely why PTP1B knockout mice are lean, insulin-hypersensitive, and resistant to diet-induced obesity — and why PTP1B inhibitors are among the most validated drug targets for type 2 diabetes and obesity. Several inhibitors have reached clinical trials (ertiprotafib, trodusquemine, ISIS PTP1BRx), though selectivity challenges remain.

The Evidence

The foundational genetics were established by Bento et al. 200444 Bento et al. 2004
Bento JL et al. Association of protein tyrosine phosphatase 1B gene polymorphisms with type 2 diabetes. Diabetes, 2004, who showed that 23 noncoding PTPN1 SNPs cluster in a single 100-kb LD block. All associated variants fall within introns 1 through 8. The risk haplotype confers an odds ratio of approximately 1.3 for T2D, is carried by roughly 35% of the population, and accounts for a population-attributable risk of 17-20%.

Florez et al. 200455 Florez et al. 2004
Florez JC et al. Association of protein tyrosine phosphatase 1B gene polymorphisms with measures of glucose homeostasis in Hispanic Americans: the IRAS Family Study. Diabetes, 2004 extended this to 811 Hispanic Americans from the IRAS Family Study, finding that all 20 common SNPs in the same LD block associated significantly with both the insulin sensitivity index (p = 0.003–0.044) and fasting glucose (p < 0.001–0.029). Eight haplotypes showed independent directional effects on insulin sensitivity and fasting glucose, confirming dose-response relationships within the block.

The rs6067484 variant specifically was studied by Ruchat et al. 201066 Ruchat et al. 2010
Ruchat SM et al. PTPN1 polymorphisms are associated with total and low-density lipoprotein cholesterol. Eur J Cardiovasc Prev Rehabil, 2010 in 382 Dutch Caucasian men, where the minor G allele associated with higher total cholesterol and LDL-C in men with BMI below 26 kg/m². This BMI-stratified finding suggests that in lean individuals — where adiposity is not yet masking genetic effects on lipid metabolism — the G allele's enhancement of PTP1B activity has a measurable impact on cholesterol clearance, consistent with PTP1B's role in hepatic insulin signaling and lipoprotein metabolism.

A 2021 Japanese intervention study77 2021 Japanese intervention study
Tanaka M et al. Association of PTPN1 gene polymorphism with the effects of weight reduction therapy on bodyweight and glycolipid profiles in obese patients. Obes Res Clin Pract, 2021 in 447 obese patients found only nominal associations for rs6067484 with waist circumference response to weight loss therapy, while the linked variant rs3787348 showed more robust effects on BMI and leptin reduction. This positions rs6067484 as a haplotype tag with modest independent effect size rather than the primary functional variant.

Practical Actions

The genetic signal from rs6067484 — and the PTPN1 locus broadly — is biologically tractable. PTP1B is not a passive bystander; it is an enzyme whose activity can be modulated by diet and lifestyle. Acute aerobic exercise rapidly reduces PTP1B activity in skeletal muscle and liver, extending the active life of the insulin receptor. Reducing refined carbohydrate load directly reduces the metabolic demand for insulin signaling, lessening the cost of faster-clearing insulin pulses. For lean individuals with the G allele, attention to LDL cholesterol is warranted given the cholesterol-raising signal in lean carriers.

The haplotype block that includes rs6067484 provides genetic context that should be interpreted alongside other variants in the PTPN1 region (rs3787348, rs6020611, rs1060402) as well as insulin-signaling pathway partners. The combined signal is more informative than any single SNP in isolation.

Interactions

The most relevant interaction is with the closely linked PTPN1 variant rs3787348. Both rs6067484 and rs3787348 tag the same ~100-kb risk haplotype block, and the latter showed stronger prediction of weight loss response in the Tanaka 2021 study. Carriers of the G allele at rs6067484 who also carry the T allele at rs3787348 may represent the most extreme expression of the PTPN1 risk haplotype, with reduced insulin and leptin sensitivity compounding effects on both glucose metabolism and body weight response to intervention.

PTPN1 variants interact biologically with the leptin receptor gene (LEPR) — animal studies show that PTP1B × leptin receptor interactions influence insulin sensitivity and acute insulin response. Carriers of risk alleles at both PTPN1 and LEPR may experience compounded hypothalamic leptin resistance, making weight management more challenging through both appetite and energy-expenditure mechanisms simultaneously.

Nutrient Interactions

glucose altered_metabolism

Genotype Interpretations

What each possible genotype means for this variant.

AA Low PTP1B Activity Normal

Two A alleles — standard PTPN1 function, normal insulin and leptin sensitivity

You carry two copies of the A allele at rs6067484 — the common reference genotype, present in approximately 64% of the global population. This genotype is not associated with elevated PTP1B expression from this locus. Your insulin receptor and leptin receptor signals are not shortened by this particular PTPN1 variant.

Roughly 64% of people of European descent share this genotype. You do not carry the PTPN1 noncoding risk haplotype at this tag SNP, and there is no elevated T2D or LDL risk attributable to this variant.

AG Moderate PTP1B Activity Intermediate

One G allele — mild PTPN1 risk haplotype tag, modest insulin resistance signal

The PTPN1 LD block spans from intron 1 through intron 8 of the gene. The rs6067484 G allele is a tag SNP for the risk haplotype identified in multiple Caucasian and Hispanic cohorts. The mechanism — increased mRNA stability from a 3'-UTR variant in the same block — results in more PTP1B protein in muscle and liver, shortening the active duration of the insulin receptor and JAK2 (the first step in leptin signaling).

In the Florez 2004 IRAS Family Study (n=811 Hispanic Americans), all common SNPs in this block associated with the insulin sensitivity index (p = 0.003–0.044) and fasting glucose, demonstrating consistent directional effects across multiple metabolic phenotypes.

The Ruchat 2010 Dutch study specifically linked rs6067484 G allele to elevated total cholesterol and LDL-C in lean men, suggesting the lipid effect is most visible before adiposity-related dyslipidemia masks the genetic signal.

GG High PTP1B Activity High Risk

Two G alleles — elevated PTPN1 expression, reduced insulin and leptin sensitivity

PTP1B's role as the primary phosphatase that terminates insulin receptor signaling means that elevated PTP1B expression from homozygous PTPN1 risk haplotype carriage produces a consistent impairment across multiple metabolic phenotypes. The haplotype's functional variant — a 3'-UTR element that stabilizes PTPN1 mRNA in skeletal muscle — produces more PTP1B protein, and two copies of the haplotype amplify this effect.

The consequence is both faster insulin signal termination (requiring higher insulin secretion to achieve the same glucose uptake) and faster JAK2 dephosphorylation (reducing leptin's thermogenic and appetite- suppressing effects in the hypothalamus). The Bento 2004 study estimated a population-attributable risk of 17-20% for T2D from the risk haplotype — one of the highest PAR estimates among any noncoding T2D-associated locus.

PTP1B inhibitors (ertiprotafib, trodusquemine, ISIS PTP1BRx) are actively in clinical development precisely because of the PTP1B-insulin/leptin connection validated by human genetics. For GG carriers, the biology directly supports interventions that reduce insulin demand (low-glycemic diet, reduced refined carbohydrate load) and enhance insulin sensitivity (aerobic exercise, weight management, sleep).